Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of providing universal access to Pirfenidone and Nintedanib for people with Idiopathic Pulmonary Fibrosis.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for producing evidence-based guidance for the National Health Service on whether medicines represent a clinically and cost-effective use of resources. NICE has published guidance recommending nintedanib and pirfenidone as options for treating adults with idiopathic pulmonary fibrosis if the person has a forced vital capacity between 50% and 80%. NICE is currently considering whether an update to this guidance is required and expects to inform stakeholders of the outcome in April 2021.